Gene · 8764
Papers3,537
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,021 to 1,040 of 3,537
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification and validation of a novel cellular senescence-related lncRNA prognostic signature for predicting immunotherapy response in stomach adenocarcinoma. | Front Genet | 2022 | 36092903 | PubTator, text mining | PubMed |
| Development and validation of a novel endoplasmic reticulum stress-related lncRNA prognostic signature and candidate drugs in breast cancer. | Front Genet | 2022 | 36092873 | PubTator, text mining | PubMed |
| Bioinformatics analysis of the prognostic and immunotherapeutic significance of NPRL2 in stomach adenocarcinoma. | J Gastrointest Oncol | 2022 | 36092347 | PubTator, text mining | PubMed |
Machine learning-based screening of an epithelial-mesenchymal transition-related long non-coding RNA signature reveals lower-grade glioma prognosis and the tumor microenvironment and predicts antitumor therapy response. | Front Mol Biosci | 2022 | 36090045 | PubTator, text mining | PubMed |
| Bone marrow free immune checkpoints as a potential biomarker for differential diagnosis of acquired bone marrow failures. | J Clin Lab Anal | 2022 | 36086857 | PubTator, text mining | PubMed |
| BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM. | Front Immunol | 2022 | 36081508 | PubTator, text mining | PubMed |
| Delving into the Heterogeneity of Different Breast Cancer Subtypes and the Prognostic Models Utilizing scRNA-Seq and Bulk RNA-Seq. | Int J Mol Sci | 2022 | 36077333 | PubTator, text mining | PubMed |
| Heparan Sulfate and Sialic Acid in Viral Attachment: Two Sides of the Same Coin? | Int J Mol Sci | 2022 | 36077240 | PubTator, text mining | PubMed |
| Circulating tumor DNA in Hodgkin lymphoma. | Ann Hematol | 2022 | 36074181 | PubTator, text mining | PubMed |
| Efficacy Evaluation of Inflammatory Mediators in the Treatment of Multiple Myeloma with Daratumumab. | J Oncol | 2022 | 36065307 | PubTator, text mining | PubMed |
| Identification of a prognostic model based on costimulatory molecule-related subtypes and characterization of tumor microenvironment infiltration in acute myeloid leukemia. | Front Genet | 2022 | 36061194 | PubTator, text mining | PubMed |
| Pan-cancer analysis of the angiotensin II receptor-associated protein as a prognostic and immunological gene predicting immunotherapy responses in pan-cancer. | Front Cell Dev Biol | 2022 | 36060798 | PubTator, text mining | PubMed |
| The expression and significance of efferocytosis and immune checkpoint related molecules in pancancer samples and the correlation of their expression with anticancer drug sensitivity. | Front Pharmacol | 2022 | 36059952 | PubTator, text mining | PubMed |
| The Pyroptosis-Related Risk Genes APOBEC3D, TNFRSF14, and RAC2 Were Used to Evaluate Prognosis and as Tumor Suppressor Genes in Breast Cancer. | J Oncol | 2022 | 36059808 | PubTator, text mining | PubMed |
| Characterization of coagulation-related gene signature to predict prognosis and tumor immune microenvironment in skin cutaneous melanoma. | Front Oncol | 2022 | 36059641 | PubTator, text mining | PubMed |
| Human repair-related Schwann cells adopt functions of antigen-presenting cells in vitro. | Glia | 2022 | 36054432 | PubTator, text mining | PubMed |
| Predictive value of drug efficacy by M6A modification patterns in rheumatoid arthritis patients. | Front Immunol | 2022 | 36052084 | PubTator, text mining | PubMed |
| Integrated analysis of necroptosis-related lncRNAs for prognosis and immunotherapy of patients with pancreatic adenocarcinoma. | Front Genet | 2022 | 36051690 | PubTator, text mining | PubMed |
| IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia. | J Clin Invest | 2022 | 36047494 | PubTator, text mining | PubMed |
| Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. | Nat Med | 2022 | 36038629 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8764/papers?page=52